Citius Pharmaceuticals, Inc. — Director's Dealing 2018

Mar 29, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Citius Pharmaceuticals, Inc. (CTXR)
CIK: 0001506251
Period of Report: 2018-03-28

Reporting Person: HOLUBIAK MYRON Z (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-28	Common Stock	P	2915	$3.09	Acquired	519882	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Purchase Common Stock	$8.10	2025-10-01	Common Stock (26667)	26667	Direct
Options to Purchase Common Stock	$3.45	2027-09-13	Common Stock (40000)	40000	Direct
Warrant to Purchase Common Stock	$6.21	2019-06-12	Common Stock (19615)	19615	Direct

Footnotes

F1: The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of common stock of the Company (the "Common Stock") vested on October 1, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015. The option was issued pursuant to the Company's 2014 Stock Incentive Plan.

F2: One-third of the shares of the Company's common stock underlying the grant vest on the first anniversary of the vesting commencement date, September 13, 2018. The remaining shares of the Company's common stock underlying the grant vest in equal monthly installments at the end of each month for two years following the initial vest, provided the Reporting Person continues to serve as a member of the Company's Board of Directors as of each such vesting date.

F3: The warrant is fully vested and exercisable immediately.